Related Experiment Video
Updated: Jun 7, 2026
Characterization and Isolation of Mouse Primary Microglia by Density Gradient Centrifugation
Published on: February 16, 2018
Minocycline prevents osmotic demyelination syndrome by inhibiting the activation of microglia
Haruyuki Suzuki1, Yoshihisa Sugimura, Shintaro Iwama
1Department of Endocrinology and Diabetes, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Abstract:
Rapid correction of chronic hyponatremia can lead to osmotic demyelination syndrome (ODS), a severe demyelination disease. The microglia that accumulate in the demyelinative lesions may play a detrimental role in the pathogenesis of ODS by producing proinflammatory cytokines, suggesting that they may be a target for therapeutic intervention. Here, we investigated whether minocycline, a selective and potent inhibitor of microglial activation, could protect against ODS in rats. We induced hyponatremia by liquid diet feeding and dDAVP infusion. Rapid correction of the hyponatremia 7 days later resulted in neurologic impairment with severe demyelinative lesions. Activated microglia accumulated at the site of demyelination. Treatment with minocycline within 24 hours of rapid correction, however, was protective: rats exhibited minimal neurologic impairment, and survival improved. Histologic analysis showed that minocycline inhibited demyelination and suppressed the accumulation of microglia at the site of demyelination. Real-time RT-PCR and immunohistochemical analyses showed that minocycline inhibited the activity of microglia and the expression of inflammatory cytokines (e.g. IL-1β, inducible nitric-oxide synthase, and TNF-α), monocyte chemoattractant protein-1, and matrix metalloproteinase-12 in microglia. These results demonstrate that minocycline can protect against ODS by inhibiting the activation and accumulation of microglia at the site of demyelinative lesions, suggesting its possible use in clinical practice.
Insights
Minocycline treatment protected rats from osmotic demyelination syndrome (ODS) by inhibiting microglial activation and reducing inflammation. This suggests minocycline may be a potential therapy for ODS, a severe demyelination disease.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Rapid correction of chronic hyponatremia can cause osmotic demyelination syndrome (ODS).
- Microglia activation and subsequent inflammation are implicated in ODS pathogenesis.
- Targeting microglia may offer a therapeutic strategy for ODS.
Purpose of the Study:
- To investigate the protective effects of minocycline, a microglial inhibitor, against ODS in a rat model.
- To determine if minocycline can prevent demyelination and neurological deficits associated with ODS.
Main Methods:
- Hyponatremia was induced in rats via liquid diet and dDAVP infusion.
- Rapid correction of hyponatremia triggered ODS, characterized by neurological impairment and demyelination.
- Minocycline was administered within 24 hours of rapid correction, followed by histological and molecular analyses.
Main Results:
- Minocycline treatment significantly improved neurological function and survival rates in ODS rats.
- Histological analysis revealed inhibited demyelination and reduced microglial accumulation in minocycline-treated rats.
- Minocycline suppressed microglial activation and the expression of pro-inflammatory cytokines (IL-1β, iNOS, TNF-α) and chemokines (MCP-1).
Conclusions:
- Minocycline demonstrates protective effects against ODS in rats.
- Inhibition of microglial activation and inflammation is the likely mechanism of minocycline's efficacy.
- Minocycline holds potential as a therapeutic agent for preventing or treating osmotic demyelination syndrome in clinical settings.
